Physician profile
Isha Shrestha
NPI 1477965507
$7,134.03
in general payments reported to CMS, 2019-2025
32 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $1,065 · 2021: $958 · 2022: $907 · 2023: $282 · 2024: $2,228 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089 · Travel and Lodging: $648 · Education: $57.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.60 |
| Travel and Lodging | $647.88 |
| Education | $57.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,616.16 | 2024-2025 | Minimed 780g |
| Amgen INC. | $997.43 | 2019-2025 | Tepezza |
| Novo Nordisk INC | $550.57 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $440.44 | 2020-2025 | |
| Tandem Diabetes Care, INC. | $412.25 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.23 | 2020-2025 | Jardiance |
| Mannkind Corporation | $392.25 | 2022-2025 | Afrezza |
| Lilly USA, LLC | $376.33 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Insulet Corporation | $333.41 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $227.10 | 2020-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $201.48 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $166.03 | 2019-2025 | Tymlos |
| Abbott Laboratories | $143.12 | 2020-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $108.07 | 2022 | |
| Amarin Pharma, INC. | $105.06 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $79.93 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $78.20 | 2023-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $77.83 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.93 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $42.58 | 2025 | Yorvipath |
| Janssen Pharmaceuticals, INC | $39.42 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $35.34 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $35.10 | 2020-2024 | Strensiq |
| Lifescan, INC. | $33.35 | 2020-2022 | |
| Sequel Med Tech, LLC | $30.05 | 2025 | Twiist |
| Dexcom, INC. | $23.95 | 2020 | |
| Halozyme INC | $21.87 | 2023 | |
| Medicure Pharma INC. | $21.72 | 2021 | |
| Ibsa Pharma INC. | $17.63 | 2023 | Tirosint, Licart |
| Antares Pharma, INC. | $16.97 | 2021 | |
| Medtronic Minimed, INC. | $16.23 | 2020 | |
| Companion Medical, INC. | $16.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isha Shrestha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.